Selected problems of biologic therapy in rheumatoid arthritis patients – inefficacy of several biologic therapies. Case reports

Introduction of biologic disease modifying antirheumatic drugs (DMARDs) to the treatment of rheumatoid arthritis (RA) is a major breakthrough. However, primary or secondary inefficacy of biologic therapy is an important practical problems. In this study we presented two cases of RA patients treated with many biologics, because of their inefficacy.

REFERENCES (15)

Pisetsky DS, Ward MM. Advances in the treatment of inflammatory arthritis. Best Pract Res Clin Rheumatol 2011; 26: 251-261.

Google Scholar

Aquarwal SK. Biologic agents in rheumatoid arthritis: an update for managed care professionals. J Manag Care Pharm 2011; 17 (9 Suppl B): S14-S18.

Google Scholar

Smolen JS, Aletaha D, Bijlsma JW, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-975.

Google Scholar

Głuszko P, Filipowicz-Sosnowska A, Tłustochowicz W. Zalecenia postępowania diagnostycznego i terapeutycznego. Reumatoidalne zapalenie stawów. Reumatologia 2012; 50: 83-90.

Google Scholar

Dixon WG, Watson K, Lunt M, et al. British Society of Rheumatology Biologics Register. Rates of serious infection, including side-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Arthritis Rheum 2006; 54: 2368-2376.

Google Scholar

Gómez-Reino JJ, Carmona L, Valverde VR, et al. BIOBADASTER group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003; 48: 2122-2127.

Google Scholar

Failla V, Sabatiello M, Lebas E, et al. Cutaneous adverse effects of TNFαlpha antagonists. Rev Med Liege 2012; 67 Spec No: 3-7. .

Google Scholar

Leqerré T, Vittecoq O, Klemmer N, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or a spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006; 33: 1307-1314.

Google Scholar

Wiland P. Postępowanie w niepowodzeniu stosowania leków blokujących TNF- u chorych na reumatoidalne zapalenie stawów. Reumatologia 2008; 46: 159-167.

Google Scholar

10.

Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69: 387-393.

Google Scholar

11.

Du Pan SM, Scherer A, Gabay C, et al. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012; 71: 997-999.

Google Scholar

12.

Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007; 56: 1417-1423.

Google Scholar

13.

Greenberg JD, Reed G, Decktor D, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 2012; 71: 1134-1142.

Google Scholar

14.

Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 909-920.

Google Scholar

15.

Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR, et al. Insulin resistance in rheumatoid arthritis: the impact of the anti-TNF-αlpha therapy. Ann N Y Acad Sci 2010; 1193: 153-159.

Google Scholar

Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Submit your paper

eISSN:	2084-9834
ISSN:	0034-6233